Journal Article

Effectiveness of a computerized clinical decision support system for prevention of glucocorticoid-induced osteoporosis

Sonoyama, Tomohiro, Kosaka, Shinji, Ohta, Yoshinori, Sakuma, Mio, Matsumoto, Chisa, Takeuchi, Jiro, Morimoto, Takeshi, Nakamura, Tsukasa, Morikawa, Toru

2022

Overview

Glucocorticoids are widely used for a variety of diseases, but the prevention of glucocorticoid-induced osteoporosis is sometimes neglected. Therefore, the effectiveness of a computerized clinical decision support system (CDSS) to improve the performance rate of preventive care for glucocorticoid-induced osteoporosis was evaluated. We conducted a prospective cohort study of outpatients who used glucocorticoids for three months or longer and who met the indication for preventive care based on a guideline. The CDSS recommended bisphosphonate (BP) prescription and bone mineral density (BMD) testing based on the risk of osteoporosis. The observation period was one year (phase 1: October 2017–September 2018) before implementation and the following one year (phase 2: October 2018–September 2019) after implementation of the CDSS. Potential alerts were collected without displaying them during phase 1, and the alerts were displayed during phase 2. We measured BP prescriptions and BMD testing for long-term prescription of glucocorticoids. A total of 938 patients (phase 1, 457 patients; phase 2, 481 patients) were included, and the baseline characteristics were similar between the phases. The median age was 71 years, and men accounted for 51%. The primary disease for prescription of glucocorticoids was rheumatic disease (28%), followed by hematologic diseases (18%). The prevalence of patients who needed an alert for BP prescription (67% vs. 63%, P = 0.24) and the acceptance rate of BP prescription (16% vs. 19%, P = 0.33) were similar between the phases. The number of patients who had orders for BMD testing was significantly increased (4% vs. 24%, P < 0.001) after CDSS implementation. The number of patients who needed an alert for BMD testing was significantly decreased from 93% in phase 1 to 87% in phase 2 (P = 0.004). In conclusion, the CDSS significantly increased BMD testing in patients with a higher risk of glucocorticoid-induced osteoporosis, but did not increase BP prescription.

• Publisher: Nature Publishing Group UK,Nature Portfolio
• Subject: 692/499 / 692/700 / Aged / Bone Density / Bone Density Conservation Agents - therapeutic use / Decision Support Systems, Clinical / Diphosphonates - therapeutic use / Glucocorticoids - adverse effects / Humanities and Social Sciences / Humans / Male / multidisciplinary / Osteoporosis - chemically induced / Osteoporosis - drug therapy / Osteoporosis - prevention & control / Prospective Studies / Science / Science (multidisciplinary)